- Home
- HFBL vs TCRX Comparison
HFBL vs TCRX Comparison
Compare HFBL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFBL | TCRX |
|---|---|---|
| Founded | 1924 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 67.3M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HFBL | TCRX |
|---|---|---|
| Price | $21.80 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 4.4K | ★ 888.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | 7.69 | ★ 12.28 |
| EPS | ★ 1.55 | N/A |
| Revenue | $1,303,000.00 | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | $14.22 | ★ N/A |
| Revenue Growth | 17.49 | ★ 266.65 |
| 52 Week Low | $12.83 | $0.83 |
| 52 Week High | $24.00 | $2.57 |
Technical Indicators
Market Signals| Indicator | HFBL | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 37.24 |
| Support Level | $18.49 | N/A |
| Resistance Level | $24.00 | $1.21 |
| Average True Range (ATR) | 0.73 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 49.38 | 0.81 |
Price Performance
Historical ComparisonAbout HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.